The present invention relates to compounds of the Formula (I), wherein X1 and X2 independently represent O, NH or S; R1 and R2 are independently selected from the group consisting of a C1-C30 hydrocarbyl group, an
amino acid bonded via an
amide bond or
a peptide bonded via an
amide bond each having up to 200 amino acids, the conjugated residue X1 or X2 in this case being NH, and
hydrogen, both radicals R1 and R2 preferably not being H; and R3 is a residue selected from group consisting of —S—R6, wherein R6 is a C1-C30 hydrocarbyl group, at least one of R1 and R2 not being H when X1 and X2 are
oxygen, —S—CH2—CH(NH2)(COOH) (
cysteine-S-yl), a homologue or derivative (e.g. N-
acetyl cysteine-S-yl) thereof,
a peptide having up to 200 amino acids which contains at least one
amino acid radical with a
thiol group, preferably a
cysteine radical, and is bonded via the
thio sulfur, preferably via the
cysteine sulfur (
peptide-S-yl),
coenzyme A which is bonded via a
thiol group or fragments thereof,
acyl carrier protein bonded via a
thiol group, and
dihydrolipoic acid bonded via a
thiol group; and pharmaceutically acceptable salts thereof. The present invention also relates to the use of these compounds for preparing a
drug, drugs containing the same and their use for the therapy of diseases such as
autoimmune disease, NF-kappaB mediated diseases,
psoriasis, psoriatic
arthritis, neurodermitis, enteris regionalis Crohn, cardiac insufficiency, chronic
obstructive pulmonary diseases and
asthma and in
transplantation medicine.